Evidence map›Paper›PMID 36556425›Full record

ArticleLife (Basel, Switzerland)2022

Mortality in Pedigrees with Acute Intermittent Porphyria.

Rochus Neeleman, Kyra Musters, Margreet Wagenmakers, Sophie Mijnhout, Edith Friesema, Eric Sijbrands, Janneke Langendonk

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rochus NeelemanErasmus MC, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Expertcenter Rotterdam, University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.ORCID 0000-0003-0286-1552
Kyra MustersErasmus MC, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Expertcenter Rotterdam, University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.
Margreet WagenmakersErasmus MC, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Expertcenter Rotterdam, University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.ORCID 0000-0003-2587-0283
Sophie MijnhoutIsala Clinics, Department of Internal Medicine, 8025AB Zwolle, The Netherlands.ORCID 0000-0003-1086-4294
Edith FriesemaErasmus MC, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Expertcenter Rotterdam, University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.ORCID 0000-0001-7743-1907
Eric SijbrandsErasmus MC, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Expertcenter Rotterdam, University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.
Janneke LangendonkErasmus MC, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Expertcenter Rotterdam, University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.ORCID 0000-0002-4899-7239
Erasmus MC · NLIsala · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High mortality rates have been reported in historical cohorts of acute intermittent porphyria (AIP) patients. The mortality associated with (hydroxymethylbilane synthase) HMBS variant heterozygosity is unknown. This study estimates all-cause mortality in pedigrees with HMBS gene variants that cause AIP. We collected data on the lifespan of individuals in Dutch AIP pedigrees and performed analyses using the family tree mortality ratio method. This gave us standardized mortality ratios for these pedigrees compared to the Dutch general population as a primary outcome. Between 1810 and 2017, the overall mortality in these pedigrees was identical to that of the general Dutch population: (SMR 1.01, p = 0.441). However, compared with the general population the SMR was significantly higher in women aged 45−64 years (SMR 1.99, p = 0.00003), which was based on excess mortality between 1915 and 1964 (SMR 1.94, p < 0.00002). In men aged 70−74 years, the SMR was 1.55 (p = 0.0021), based on excess mortality that occurred between 1925 and 1964 (SMR 1.92, p = 0000000003). Overall, mortality from HMBS variant heterozygosity was not increased compared with the general population. Severe excess mortality occurred in young women and old men between 1915 and 1964. Heterozygotes reached a normal lifespan during the past half-century, in parallel with disease awareness and the prevention of new attacks through family counselling.

Indexed as

acute hepatic porphyriaacute intermittent porphyriahydroxymethylbilane synthasestandardized mortality ratio

Identifiers

PMID36556425
PMCPMC9785653
OpenAlexW4311955493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.